NASDAQ:GMDA Gamida Cell - GMDA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Gamida Cell Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $1.70 +0.03 (+1.79%) (As of 02/3/2023 12:00 PM ET) Add Compare Share Share Today's Range$1.61▼$1.7050-Day Range$1.15▼$1.6752-Week Range$1.10▼$4.72Volume178,679 shsAverage Volume456,434 shsMarket Capitalization$126.44 millionP/E RatioN/ADividend YieldN/APrice Target$12.80 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Gamida Cell MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside668.2% Upside$12.80 Price TargetShort InterestBearish6.17% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.18) to ($0.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.57 out of 5 starsMedical Sector896th out of 1,029 stocksBiological Products, Except Diagnostic Industry143rd out of 169 stocks 3.5 Analyst's Opinion Consensus RatingGamida Cell has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.80, Gamida Cell has a forecasted upside of 668.2% from its current price of $1.67.Amount of Analyst CoverageGamida Cell has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.17% of the outstanding shares of Gamida Cell have been sold short.Short Interest Ratio / Days to CoverGamida Cell has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Gamida Cell has recently increased by 15.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGamida Cell does not currently pay a dividend.Dividend GrowthGamida Cell does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GMDA. Previous Next 0.6 News and Social Media Coverage Search Interest22 people have searched for GMDA on MarketBeat in the last 30 days. This is an increase of 47% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Gamida Cell to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gamida Cell insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.40% of the stock of Gamida Cell is held by insiders.Percentage Held by Institutions56.19% of the stock of Gamida Cell is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Gamida Cell are expected to grow in the coming year, from ($1.18) to ($0.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gamida Cell is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gamida Cell is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGamida Cell has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Gamida Cell (NASDAQ:GMDA) StockGamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Boston, MA.Read More Receive GMDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gamida Cell and its competitors with MarketBeat's FREE daily newsletter. Email Address GMDA Stock News HeadlinesJanuary 16, 2023 | finance.yahoo.comGamida Cell (GMDA) Upgraded to Buy: Here's WhyDecember 12, 2022 | finance.yahoo.comGamida Cell Announces Closing of $25 Million Financing With HighbridgeFebruary 3, 2023 | Investing Trends (Ad)The Humble Mineral at the Heart of the EV Revolution (Not Lithium)You may know of graphite as what's in the tip of a No. 2 pencil, but it is the key to many forms of renewable energy. Today, this humble mineral is at the epicenter of the electric car revolution. Because what most people don't know is today's EV batteries contain more than 220 pounds of graphite – more than lithium, copper or aluminum!November 21, 2022 | finance.yahoo.comGamida Cell Provides Regulatory Update on OmidubicelNovember 14, 2022 | finance.yahoo.comGamida Cell Reports Third Quarter 2022 Financial Results and Provides Company UpdateNovember 10, 2022 | finance.yahoo.comGamida Cell to Present Corporate Highlights at the Jefferies London Healthcare ConferenceNovember 7, 2022 | finance.yahoo.comGamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and WebcastNovember 7, 2022 | finance.yahoo.comGDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ CancersFebruary 3, 2023 | Investing Trends (Ad)The Humble Mineral at the Heart of the EV Revolution (Not Lithium)You may know of graphite as what's in the tip of a No. 2 pencil, but it is the key to many forms of renewable energy. Today, this humble mineral is at the epicenter of the electric car revolution. Because what most people don't know is today's EV batteries contain more than 220 pounds of graphite – more than lithium, copper or aluminum!November 3, 2022 | finance.yahoo.comGamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual MeetingOctober 10, 2022 | finance.yahoo.comGamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the MesaSeptember 29, 2022 | markets.businessinsider.comGamida Cell: Omidubicel Follow Up Data Shows 63% Overall Survival At Three YearsSeptember 29, 2022 | finance.yahoo.comLong-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology MeetingSeptember 28, 2022 | marketwatch.comGamida Cell Shares Slide Premarket After Public Offering, Financing >GMDASeptember 28, 2022 | finance.yahoo.comGamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary SharesSeptember 28, 2022 | finance.yahoo.comGamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million FinancingSeptember 19, 2022 | marketwatch.comGamida Cell Names Abigail L. Jenkins as President, CEOSeptember 19, 2022 | markets.businessinsider.comGamida Cell Appoints Abigail Jenkins To Succeed Julian Adams As President And CEOSeptember 19, 2022 | finance.yahoo.comGamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative TherapiesSeptember 12, 2022 | finance.yahoo.comGamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect MeetingAugust 17, 2022 | msn.comEarningsAugust 15, 2022 | fool.comGamida Cell Ltd. (GMDA) Q2 2022 Earnings Call TranscriptAugust 15, 2022 | seekingalpha.comGamida Cell Ltd. (GMDA) CEO Julian Adams on Q2 2022 Results - Earnings Call TranscriptAugust 15, 2022 | finance.yahoo.comGamida Cell Reports Second Quarter 2022 Financial Results and Provides Company UpdateAugust 10, 2022 | finance.yahoo.comGamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201August 9, 2022 | finance.yahoo.comThese 2 Penny Stocks Are Poised for a Big Rally, Says OppenheimerAugust 8, 2022 | finance.yahoo.comGamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and WebcastSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GMDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gamida Cell and its competitors with MarketBeat's FREE daily newsletter. Email Address GMDA Company Calendar Last Earnings11/14/2022Today2/03/2023Next Earnings (Estimated)3/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GMDA CUSIPN/A CIK1600847 Webwww.gamida-cell.com Phone(713) 400-6400FaxN/AEmployees166Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.80 High Stock Price Forecast$22.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+653.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-387.05% Return on Assets-70.54% Debt Debt-to-Equity Ratio5.31 Current Ratio2.76 Quick Ratio2.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.74 per share Price / Book2.30Miscellaneous Outstanding Shares74,380,000Free Float71,852,000Market Cap$126.44 million OptionableNot Optionable Beta1.67 Key ExecutivesAbigail L. JenkinsPresident, Chief Executive Officer & DirectorMichele I. KorfinChief Operating & Commercial OfficerShai LankryChief Financial OfficerRonit SimantovChief Medical & Scientific OfficerYona GeffenVice President-Research & DevelopmentKey CompetitorsCEL-SCINYSE:CVMInstil BioNASDAQ:TILPrecision BioSciencesNASDAQ:DTILGenenta ScienceNASDAQ:GNTABlack Diamond TherapeuticsNASDAQ:BDTXView All CompetitorsInsiders & InstitutionsStock Yards Bank & Trust Co.Sold 20,000 shares on 2/2/2023Ownership: 0.067%Simplex Trading LLCSold 9,300 shares on 2/2/2023Ownership: 0.000%FNY Investment Advisers LLCBought 153,000 shares on 1/10/2023Ownership: 0.258%BlackRock Inc.Bought 10,092 shares on 11/15/2022Ownership: 0.776%Marshall Wace LLPBought 143,968 shares on 11/15/2022Ownership: 0.623%View All Insider TransactionsView All Institutional Transactions GMDA Stock - Frequently Asked Questions Should I buy or sell Gamida Cell stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GMDA shares. View GMDA analyst ratings or view top-rated stocks. What is Gamida Cell's stock price forecast for 2023? 5 brokers have issued twelve-month price targets for Gamida Cell's shares. Their GMDA share price forecasts range from $7.00 to $22.00. On average, they predict the company's share price to reach $12.80 in the next year. This suggests a possible upside of 666.5% from the stock's current price. View analysts price targets for GMDA or view top-rated stocks among Wall Street analysts. How have GMDA shares performed in 2023? Gamida Cell's stock was trading at $1.29 at the beginning of 2023. Since then, GMDA shares have increased by 29.5% and is now trading at $1.67. View the best growth stocks for 2023 here. Are investors shorting Gamida Cell? Gamida Cell saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 4,590,000 shares, an increase of 15.3% from the December 31st total of 3,980,000 shares. Based on an average daily trading volume, of 522,700 shares, the days-to-cover ratio is presently 8.8 days. View Gamida Cell's Short Interest. When is Gamida Cell's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023. View our GMDA earnings forecast. How were Gamida Cell's earnings last quarter? Gamida Cell Ltd. (NASDAQ:GMDA) released its quarterly earnings data on Monday, November, 14th. The company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.02. What other stocks do shareholders of Gamida Cell own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gamida Cell investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Pennsylvania Real Estate Investment Trust (PEI), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB), Enerplus (ERF) and Novan (NOVN). When did Gamida Cell IPO? (GMDA) raised $50 million in an initial public offering (IPO) on Friday, October 26th 2018. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager. What is Gamida Cell's stock symbol? Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA." Who are Gamida Cell's major shareholders? Gamida Cell's stock is owned by a number of institutional and retail investors. Top institutional shareholders include FNY Investment Advisers LLC (0.26%), Stock Yards Bank & Trust Co. (0.07%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Abigail L Jenkins and Stephen T Wills. View institutional ownership trends. How do I buy shares of Gamida Cell? Shares of GMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Gamida Cell's stock price today? One share of GMDA stock can currently be purchased for approximately $1.67. How much money does Gamida Cell make? Gamida Cell (NASDAQ:GMDA) has a market capitalization of $124.21 million. The company earns $-89,790,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis. How many employees does Gamida Cell have? The company employs 166 workers across the globe. How can I contact Gamida Cell? Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The official website for the company is www.gamida-cell.com. The company can be reached via phone at (713) 400-6400 or via email at irpr@gamida-cell.com. This page (NASDAQ:GMDA) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.